RAPT Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

RAPT Therapeutics, based in South San Francisco, announced that CEO Brian Wong will present at key investor conferences in November 2021. These include the Stifel 2021 Virtual Healthcare Conference on November 15 at 2:00 p.m. ET and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22 available on-demand at 10:00 a.m. ET. RAPT Therapeutics focuses on developing oral small molecule therapies for inflammatory diseases and oncology, with drug candidates like RPT193 and FLX475 targeting CCR4.

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the following investor conferences in November:

• Stifel 2021 Virtual Healthcare Conference – Company presentation on Monday, November 15, 2021, at 2:00 p.m. ET
• Piper Sandler 33rd Annual Virtual Healthcare Conference – Pre-recorded fireside chat available on-demand Monday, November 22, 2021, at 10:00 a.m. ET

To access the live webcast or subsequent archived recordings of the company presentations, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammatory diseases and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

 

FAQ

What are the upcoming investor conferences for RAPT Therapeutics in November 2021?

RAPT Therapeutics will present at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 2:00 p.m. ET and at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, available on-demand at 10:00 a.m. ET.

Who is presenting for RAPT Therapeutics at the November 2021 conferences?

Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics, will be presenting at the investor conferences.

Where can I access RAPT Therapeutics' conference presentations?

You can access the live webcast and archived recordings of RAPT Therapeutics' presentations on their website at https://investors.rapt.com/events-and-presentations.

What is the focus of RAPT Therapeutics' drug development?

RAPT Therapeutics focuses on discovering and developing oral small molecule therapies for significant unmet needs in inflammatory diseases and oncology.

What drug candidates is RAPT Therapeutics currently developing?

RAPT Therapeutics is developing drug candidates RPT193 and FLX475, both targeting the CCR4 receptor for the treatment of inflammatory diseases and cancer, respectively.